Aisling Capital IV, LP - 16 Jun 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
10%+ Owner
Signature
AISLING CAPITAL IV, LP, by Aisling Capital Partners IV, LP, its General Partner, by Aisling Capital Partners IV LLC, its General Partner, /s/ Andrew Schiff, Managing Member
Issuer symbol
ELEV
Transactions as of
16 Jun 2023
Net transactions value
$0
Form type
4
Filing time
21 Jun 2023, 16:09:11 UTC
Previous filing
22 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +31,238 $0.000000 31,238 16 Jun 2023 Common Stock 31,238 $1.47 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F2 This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.